Data from Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Abstract

<div>Abstract<p><b>Purpose:</b> Recent data suggest that intrinsic subtype and immune cell infiltration may predict response to trastuzumab-based therapy. We studied the interaction between these factors, changes in immune signatures following brief exposure to trastuzumab, and achievement of pathologic complete response (pCR) to subsequent preoperative trastuzumab and chemotherapy in HER2-positive breast cancer.</p><p><b>Experimental Design:</b> In patients enrolled on two multicenter trials (03-311 and 211B), tumor core biopsies were obtained at baseline and after brief exposure to single-agent trastuzumab or nab-paclitaxel. Gene expression profiles were assessed to assign PAM50 subtypes, measure immune cell activation, and were correlated with response.</p><p><b>Results:</b> The pCR rate was significantly higher in HER2-enriched tumors in the Discovery, 03-311 (36%, <i>P</i> = 0.043) dataset, as compared with other subtypes, which validated in 211B (50%, <i>P</i> = 0.048). Significant increases in a signature of immune cell admixture (Immune Index) were observed only following brief exposure to trastuzumab in HER2-enriched tumors (Discovery/03-311, <i>P</i> = 0.05; Validation/211B, <i>P</i> = 0.02). Increased Immune Index was predictive of response after brief exposure (03-311, <i>P</i> = 0.03; 211B, <i>P</i> = 0.04), but not at baseline, in addition to increased expression of a CD4<sup>+</sup> follicular helper T-cell signature (03-311, <i>P</i> = 0.05; 211B, <i>P</i> = 0.04). Brief exposure to trastuzumab significantly increased gene expression of the T-cell marker PD-1 in HER2-enriched tumors (Discovery/03-311, <i>P</i> = 0.045) and PD-1 positivity by IHC (Validation/211B, <i>P</i> = 0.035).</p><p><b>Conclusions:</b> Correlations between pCR rates, increases in Immune Index and markers of T-cell activity following brief exposure to trastuzumab in HER2-enriched tumors provide novel insights into the interaction between tumor biology, antitumor immunity, and response to treatment, and suggest potential clinically useful biomarkers in HER2<sup>+</sup> breast cancers. <i>Clin Cancer Res; 22(13); 3249–59. ©2016 AACR</i>.</p></div>